Shionogi Reports the P-III Trial Results for Ensitrelvir as a Treatment of Common COVID-19 Symptoms
Shots:
- The P-II/III (SCORPIO-SR) trial evaluates Ensitrelvir (125/250mg) vs PBO in patients (n=1,821) with mild to moderate COVID-19 across Japan, South Korea & Vietnam. The 1EP was time to resolution of 5 COVID-19 symptoms & 2EPs were change from baseline in SARS-CoV-2 RNA level on day 4 & time to first negative SARS-CoV-2 titer
- The results showed a median time to symptom resolution of 167.9hrs. vs 192.2hrs., change from baseline in SARS-CoV-2 RNA level of −2.48 log10 copies/mL vs −1.01 log10 copies/mL & a 36.2hrs. vs -29.1hrs. difference in the first negative SARS-CoV-2 titer. The results were published in JAMA Network Open
- Ensitrelvir (oral antiviral drug) was approved in Japan in 2022 (by Xocova), in Singapore in Nov 2023 & was granted the US FDA’s FTD for COVID-19 treatment
Ref: Shionogi | Image: Shionogi
Related News:- Shionogi Initiated P-I/II/III Clinical Trial (Part 2) and P-III Additional Dose Clinical Trial of S-268019 for COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
